BridgeBio Pharma is a biopharmaceutical company that discovers, develops, and commercializes medicines for patients with genetic diseases using a capital-efficient, decentralized hub-and-spoke model. The company derives revenue from direct product sales, licensing partnerships, and milestone payments, with its commercial portfolio including FDA-approved therapies for rare genetic conditions such as transthyretin amyloid cardiomyopathy and molybdenum cofactor deficiency, as well as a pipeline of late-stage programs in development for genetic disorders including achondroplasia, autosomal dominant hypocalcemia, and muscular dystrophy. BridgeBio targets underserved patient populations with scientifically grounded therapies, competing with both established pharmaceutical players and emerging developers while maintaining flexibility to expand into adjacent indications and next-generation approaches.